期刊文献+

替罗非班对大鼠心肌缺血再灌注后无复流及NF-κB激活的影响 被引量:5

Effects of tirofiban on no-reflow and activation of NF-κB after myocardial ischemia/reperfusion in rats
暂未订购
导出
摘要 目的:研究血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班对大鼠心肌缺血再灌注后无复流及NF-κB激活的影响。方法:雄性Wistar大鼠,随机分为假手术组、心肌缺血再灌注组和替罗非班治疗组(60μg/kg,再灌注前30min股静脉注射)。心肌缺血再灌注组和替罗非班治疗组采用开胸冠状动脉结扎方法,缺血90min再灌注120min建立急性心肌缺血再灌注无复流模型。观察大鼠心肌缺血、梗死及无复流范围;免疫组织化学方法半定量分析心肌细胞及微动脉核因子-κBp65(NF-κBp65)的阳性表达;测定心肌髓过氧化物酶(MPO)活性及丙二醛(MDA)含量。结果:心肌缺血再灌注组和替罗非班治疗组大鼠缺血区心肌细胞及微动脉NF-κBp65的阳性表达、心肌MPO活性、MDA含量高于假手术组;替罗非班治疗组大鼠缺血区心肌细胞及微动脉NF-κBp65的阳性表达、心肌MPO活性、MDA含量低于心肌缺血再灌注组(P<0.05);心肌无复流范围及梗死范围小于心肌缺血再灌注组(34.36%±6.04%vs52.09%±6.89%,P<0.01;80.41%±8.48%vs90.13%±5.72%,P<0.05)。结论:大鼠心肌缺血90min再灌注120min时,可发生无复流现象;替罗非班可缩小心肌无复流及梗死范围,抑制NF-κB激活,减少中性粒细胞浸润及氧自由基释放。 AIM: To investigate the effects of platelet glycoprotein Ⅱ b/Ⅲ a receptor inhibitor tirofiban on myocardial no - reflow and activation of NF - κB after acute ischemia/reperfusion in rats. METHODS : Male Wistar rats were randomized into sham operation group, control group and tirofiban treatment group. Control group and tirofiban group were subjected ischemia for 90 min by ligation of coronary artery after thoracotomy and subsequently reperfusion for 120 min to establish acute myocardial ischemia/reperfusion no -reflow models. Thioflavine S, Evans blue and triphenyhetra zolium chloride (TIC) staining were performed to evaluate the area of no - reflow (ANR), infracted area (IA) and risk area (RA) of the heart. Immunohistochemistry was used for semi - quantitative analysis of the expression of nuclear factor - κB 1965 ( NF - κB p65 ) protein in myocytes and arteriole. Activity of myeloperoxidase (MPO) and content of malondialdehyde (MDA) in risk area of the heart were detected by ultraviolet spectrophotometer. RESULTS: After 120 rain for reperfusion, compared to sham group, the statistical differences of higher positive expression of NF - κB p65 in myocytes and arteriole, activity of MPO and content of MDA both in control and tirofiban group were observed. Compared to control group, lower positive expression of NF - κB p65 in myocyte and arteriole, activity of MPO and content of MDA in tirofiban group were found (P 〈0. 05, P 〈0. 01 ). A markedly reduced ANR and IA were observed in tirofiban group than those in control group (34.36% ±6.04% vs 52.09% ±6.89%, P〈0.01; 80.41% ±8.48% vs90. 13% ±5.72%, P〈0.05). CONCLUSION: After myocardial ischemia/reperfusion for 120 min, no - reflow phenomenon can be observed in rats. Tirofiban reduces the areas of anatomic no - reflow and infarction, inhibits the activation of NF - κB in myocyte and arteriole, and decreases the infiltration of neutrophils and release of oxygen free radicals.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2009年第10期1892-1897,共6页 Chinese Journal of Pathophysiology
关键词 心肌再灌注损伤 无复流 血小板糖蛋白GP Ⅱb-Ⅲa复合物 NF—κB 替罗非班 Myocardial reperfusion injury No reflow Platelct glycoprotein GP Ⅱ b - Ⅲa complex NF -kappa B Tirofiban
  • 相关文献

参考文献3

二级参考文献40

  • 1赵京林,杨跃进,尤士杰,荆志成,吴永健,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.地尔硫卓对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(10):679-683. 被引量:7
  • 2许建英,杜永成,庞敏,徐永健.香烟烟雾提取物通过活化NF-κB上调小鼠巨噬细胞ICAM-1表达[J].中国病理生理杂志,2006,22(9):1843-1845. 被引量:9
  • 3高维娟,许顺江,丛斌,李淑瑾,马春玲,徐锦荣,姚玉霞,谷振勇.CCK-8抑制LPS作用下大鼠肺间质巨噬细胞NF-κB活性的cAMP-PKA通路研究[J].中国病理生理杂志,2006,22(10):1891-1895. 被引量:21
  • 4Saitoh S, Onogi F, Aikawa K, et al. Multiple endothelial injury in epicardial coronary artery induced downstream microvascular spasm as well as remodeling partly via thromboxane A2. J Am Coll Cardiol,2001,37:308-315.
  • 5Kunichika H, Ben-Yehuda O, Lafitte S, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echecardiography study. J Am Coll Cardiol,2004,43:276-283.
  • 6Lemos JA, Gibson CM, Antman EM, et al. Abciximab and early adjunctive percutaneous corona.ry intervention are associated withimproved ST-segment resolution after thrombolysis: observations fromthe TIMI 14 trial. Am Heart J, 2001,141:5928.
  • 7Mak KH, Neumann FJ, Blasini MR, et al. Recovery of coronary flow and left ventricular function after abciximab. Circulation, 1999,100:e110.
  • 8Gawaz M. Role of platelets in coronary thrombosis and repcrfusion of ischemic myocardium. Cardiovasc Res, 2004,61:498-511.
  • 9The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997, 96: 1445-1453.
  • 10Batchelor WB, Tolleson TR, Huang Y, et al. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison of measurements of platelet aggregation with aggrastat, reopro, and eptifibatide. Circulation. 2002,106: 1470-1476.

共引文献32

同被引文献58

  • 1吕宏升,朱庆生,王军,朱锦宇,赵广跃,张大伟.全自动显微镜及图像分析系统处理免疫组化图像[J].中国体视学与图像分析,2004,9(1):37-40. 被引量:63
  • 2杨跃进,赵京林,荆志成,吴永健,尤士杰,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.中药通心络对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(13):883-888. 被引量:35
  • 3黄敬泽,邱晓萍,王健.循环内皮细胞水平与糖尿病肾病的相关性及银杏达莫的干预作用[J].中国临床药理学与治疗学,2006,11(11):1309-1312. 被引量:10
  • 4姚素艳,郑德宇,李淑云,邹金发,金英.阿魏酸钠抑制Aβ_(25-35)诱导的小鼠腹腔巨噬细胞p38MAPK活化[J].中国病理生理杂志,2007,23(3):449-452. 被引量:5
  • 5Inhibition of the platelet glycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.[J].N Engl J Med,1998,338(21):1488-1497.
  • 6Schneider DJ,Herrmann HC,Lakkis N,et al.Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban[J].Am J Cardiol,2003,91(3):334-336.
  • 7Zeymer U,Schroder K,Wegscheider K,et al.ST resolution in a single electrocardiographic lead:a simple and accurate predictor of cardiac mortality in patients with fibrinolytic therapy for acute ST-elevation myocardial infarction[J].Am Heart J,2005,149(1):91-97.
  • 8Van't Hof AW,Ten Berg J,Heestermans T,et al.Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2):a multicentre,double-blind,randomised controlled trial[J].Lancet,2008,372(9638):537-546.
  • 9Niccoli G,Kharbanda RK,Crea F,et al.No-reflow:again prevention is better than treatment[J].Eur Heart J,2010,31(20):2449-2455.
  • 10Wu TG,Zhao Q,Huang WG,et al.Effect of Intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome[J].Circ J,2008,72 (10):1605-1609.

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部